In a recent study published in the
Journal of Clinical Gastroenterology
researchers investigated the role of
the probiotic Lactobacillus reuteri
DSM 17938 and L. reuteri ATCC
PTA 6475 in Helicobacter pylori
infection.
The paper concluded that the
combination product was able to
inhibit H. pylori growth and when
administered with eradication
therapy which includes antibiotic
regimens, was able to significantly
reduce antibiotic -associated side
effects.
To read the abstract, CLICK HERE.The above article was sent to subscribers in Pharmacy Daily's issue from 21 Jan 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 21 Jan 14
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.